The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT01061060

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01061060
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01061060. Randomized; quadruple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients
Condition
Type 2 Diabetes Mellitus
Condition
Peripheral Microvascular Symptoms
Intervention (Drug)
Prostaglandin I2
Intervention (Drug)
Placebo
Lead sponsor
Yonsei University (class: other)
Collaborator
Astellas Pharma Korea, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01061060
Content hash
650bdec53af29e60255dc51dac8cf86111bf5e54609cb34a903eeec4053227aa